Blog

The latest thoughts from Medicines Law & Policy partners.

The Power of TRIPS Flexibilities in Medicines Procurement

The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV).  Treatment will be a combination of...

Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...

The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...

Medicines price transparency: Ground still left to cover

Parts of this blog were previously published in the Lancet Regional Health Europe Secret medicines prices are hotly debated as European health systems struggle to...

Are gene-editing therapies patentable? A WIPO side event investigates.

On 6 December, Knowledge Ecology International (KEI) organised an interesting panel on the patentability of new gene- and cell-based medical therapies, as a side...

Some Surprises in the European Commission’s New Intellectual Property Strategy

The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...

New reports offer evidence for extending the WTO Decision on TRIPS to Covid-19 therapeutics...

In February 2024, the 13th World Trade Organization (WTO) Ministerial Conference will take place. WTO Members are expected to decide whether to extend the...